购物车
- 全部删除
- 您的购物车当前为空
Lintitript (SR 27897) 是 CCK1的选择性拮抗剂,对 CCK1和 CCK2的 EC50s 为6 nM 和200 nM。对 CCK1的 Ki 值为0.2 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
Lintitript (SR 27897) 是 CCK1的选择性拮抗剂,对 CCK1和 CCK2的 EC50s 为6 nM 和200 nM。对 CCK1的 Ki 值为0.2 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 948 | 现货 | |
2 mg | ¥ 1,430 | 现货 | |
5 mg | ¥ 2,210 | 现货 | |
10 mg | ¥ 3,190 | 现货 | |
25 mg | ¥ 4,950 | 现货 | |
50 mg | ¥ 6,540 | 现货 | |
100 mg | ¥ 8,880 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 2,490 | 现货 |
产品描述 | Lintitript (SR 27897) is a selective antagonist of CCK1 with EC50s of 6 nM and 200 nM for CCK1 and CCK2. The Ki value is 0.2 nM for CCK1. |
靶点活性 | CCK1 receptor:(ki)0.2 nM, CCK1:(EC50)6 nM |
体外活性 | Lintitript inhibited the CCK 2 site in guinea pig cortex with an IC2 of 479 nM. lintitript (0.5 nM) increased the dissociation constant of CCK on CCKA receptors with Kds between 1.8 and 7.2 nM without altering the maximum number of receptors. lintitript antagonized CCK-stimulated isolated rat pancreatic follicles in (amylase release and CCK-induced gallbladder contraction in guinea pigs with pA2s of 7.50 and 9.57). lintitript inhibited the binding of [125I]CCK to the rat pancreatic CCK1 receptor site with IC50 of 0.58 nM in a concentration-dependent manner[1]. |
体内活性 | Lintitript (1 mg/kg, i.v.) completely reversed CCK-induced amylase secretion. lintitript inhibited CCK-induced gastric and gallbladder emptying in mice with ED50s of 3 μg/kg and 72 μg/kg. lintitript (p.o.) was active in the gallbladder emptying protocol of egg yolk-induced endogenous CCK release, with an ED50 of 27 μg/kg [1]. |
别名 | 林替曲特, SR 27897 |
分子量 | 411.86 |
分子式 | C20H14ClN3O3S |
CAS No. | 136381-85-6 |
Smiles | OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl |
密度 | 1.49 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 90 mg/mL (218.5 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容